Goldman Sachs believes that Biohaven offers investors an under-the-radar opportunity to invest in a potentially best-in-class kidney disease treatment. The bank initiated coverage on the ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.

VIR-5500 ASCO GU update, VIR-5818 H2’26, ECLIPSE 1 Q4’26 + more hepatitis delta readouts. See more details here.

Unprofitable biotech Veradermics, which still needs FDA approval for its hair loss pill, surged on its debut day.

Experts highlight biotechnology's potential to drive sustainable growth and career opportunities in India's emerging ...

Explore evolving career pathways in biotechnology, emphasizing innovation, sustainability, and interdisciplinary skills from ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Over in Grant, the Tennessee Valley Authority awarded funding to a science class at Kate Duncan Smith DAR Middle School to ...

The longevity biotechnology industry is rapidly evolving with the amount of academic funding and venture investment increasing at the exponential pace. Over thirty longevity startups and approximately ...

This board strengthens Serpin Pharma’s ability to advance innovative immune‑modulating therapeutics and expand our ...

Moyom Biotechnology recently announced a strategic partnership with WPP Group, one of the world's leading global ...